ABOUT / EDITORIAL METHOD
A Reference Desk Built Around Traceable Claims
Right Peptides keeps mechanism, model, endpoint, and source in the same field of view.
What this site is
Right Peptides is an independent literature digest covering four research records under a single editorial frame. It is not a store, clinic, laboratory, manufacturer, or prescribing service. The site does not sell compounds, compare vendors, publish sourcing guidance, or recommend human doses.
The collection is intentionally mixed. KPV is a small experimental peptide with preclinical inflammatory research. Semaglutide is an approved peptide medicine with large clinical outcome trials. CJC-1295 is an investigational GHRH analogue supported by limited early human pharmacology. NAD+ is a coenzyme rather than a peptide, and its human supplement evidence centers largely on precursors. Placing them together exposes the classification and evidence errors that broad “peptide” discussions often conceal.
The editorial task is therefore not promotion or dismissal. It is calibration: summarize what each source actually tested, preserve meaningful positive findings, state safety concerns plainly, and stop where the evidence stops.
How to read the pages
Each technical page begins with a plain-English orientation and then moves through identity, mechanism, findings, reported experiences, cautions, and comparative context. Numbered citations point to the shared references page. A citation is attached near the claim it supports so the model and endpoint can be checked without guesswork.
The recurring method has three parts. First, identify the model: cell, animal, small human study, randomized trial, review, or analytical test. Second, identify the endpoint: pathway activity, biomarker, functional measure, body-weight change, or major clinical event. Third, identify the source boundary: population, comparator, duration, formulation, and uncertainty.
Anecdotal reports are labeled “anecdotal, not clinical evidence.” They are included only when present in the composed research record and are not cited as proof. Quantitative statements are linked to references. Study amounts, when necessary to understand a published result, describe that study rather than a recommendation.
Editorial stance
Right Peptides uses a calm reference-desk voice because certainty should come from the record, not from rhetoric. A preclinical result can be important and still be preclinical. A large randomized trial can support a clinical outcome and still apply only to its defined population. A changed biomarker can demonstrate biological activity without proving better health. Unknown safety is uncertainty, not evidence of either safety or harm.
The desk also distinguishes a studied compound from products of uncertain identity. Evidence generated with a defined formulation does not automatically validate a material sold under a similar name. Regulatory status is reported as context rather than as a substitute for scientific reasoning. Study sponsorship, sample size, comparator, and publication type are treated as interpretive context whenever they bear on confidence. Absence of a result is not silently turned into a negative finding.
The site is revised as its composed source corpus changes. Readers can use the citation trail to inspect the underlying literature and should treat the digest as orientation, not as personal medical guidance.